Pillar Biosciences and Hamilton Company Announce NGS Application Development and Co-Marketing Agreement

Collaboration aims to accelerate automation of rapid NGS testing

NATICK, Mass., Feb. 18, 2025 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company.

As part of this agreement, Hamilton will develop automation scripts and supporting technical and commercial literature for selected, commercially available, research-use-only (RUO) NGS panels from Pillar Biosciences for use on Hamilton’s Microlab® STAR^™ Liquid Handling Systems.  The first automation script for development will be for Pillar’s oncoReveal® Essential MPN panel.  

“Time, workflow complexity and overall testing costs are barriers for the broader adoption of localized NGS testing solutions,” said Dan Harma, CCO of Pillar Biosciences. “Combining the speed and simplicity of our NGS products and workflow with the global scale and automation capabilities of the Hamilton liquid handling systems will help ensure more laboratories, researchers and clinicians to receive the tumor profiling results they need faster, with lower labor costs and greater efficiency.”

“We are thrilled to partner with Pillar Biosciences,” said Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton. “By combining Pillar’s cutting-edge NGS solutions with Hamilton’s proven automation technology and global reach, we are providing customers with a more accessible and efficient solution to accelerate NGS testing.”

The application development and co-marketing agreement will initially cover North America, Central America, South America, New Zealand and all APAC Countries.

About Pillar Biosciences

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences has operations in Natick, MA. For more information visit pillarbiosci.com and connect with us on  LinkedIn.

About Hamilton

Hamilton Company is a global enterprise with affiliates in Reno, Nevada; Franklin, Massachusetts (both USA); and Bonaduz, Switzerland and sales offices throughout the world. Hamilton Company and its affiliated entities are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For more than 60 years, Hamilton Company has been satisfying customer needs by combining quality materials with skilled workmanship to ensure the highest level of performance. Hamilton Company’s lifelong commitment to precision and quality has earned us global ISO 9001 Certification. For more information, visit www.hamiltoncompany.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pillar-biosciences-and-hamilton-company-announce-ngs-application-development-and-co-marketing-agreement-302378085.html

SOURCE Pillar Biosciences, Inc.